DICE
Dice Therapeutics Inc
A biopharmaceutical company that developed oral pill treatments for chronic autoimmune and inflammatory diseases such as psoriasis, aiming to offer a convenient alternative to injectable biologic drugs. Founded in 2013, its name "DiCE" stands for Directed Chemical Evolution, reflecting a platform that mimics biology's own trial-and-error evolution to design medicines. In 2023 it was acquired by pharmaceutical giant Eli Lilly.
CUSIP: 23345J104HealthcareUS1 holder
Total Value
$12.80M
Total Shares
631.1K
Net Share Change
+11.7K
Activity
1 buying
Investor
Value
Shares
Weight
Change
